Comparison of bacteriological conversion and treatment outcomes among MDR-TB patients with and without diabetes in Mexico: Preliminary data

M. Muñoz-Torrico , J. Caminero Luna , G.B. Migliori , L. D’Ambrosio , J.L. Carrillo-Alduenda , H. Villareal-Velarde , A. Torres-Cruz , H. Flores-Ergara , D. Martínez-Mendoza , C. García-Sancho , R. Centis , M.Á. Salazar-Lezama , R. Pérez-Padilla
{"title":"Comparison of bacteriological conversion and treatment outcomes among MDR-TB patients with and without diabetes in Mexico: Preliminary data","authors":"M. Muñoz-Torrico ,&nbsp;J. Caminero Luna ,&nbsp;G.B. Migliori ,&nbsp;L. D’Ambrosio ,&nbsp;J.L. Carrillo-Alduenda ,&nbsp;H. Villareal-Velarde ,&nbsp;A. Torres-Cruz ,&nbsp;H. Flores-Ergara ,&nbsp;D. Martínez-Mendoza ,&nbsp;C. García-Sancho ,&nbsp;R. Centis ,&nbsp;M.Á. Salazar-Lezama ,&nbsp;R. Pérez-Padilla","doi":"10.1016/j.rppnen.2016.11.009","DOIUrl":null,"url":null,"abstract":"<div><p>Diabetes mellitus (DM) is a well-known risk factor for tuberculosis (TB). However, it is not known to what extent DM affects the outcome in patients with multidrug-resistant (MDR-TB) and extensively drug-resistant TB (XDR-TB) treated with second-line anti-TB drugs.</p><p>The objective of this study was to compare the microbiological evolution (sputum smear and culture conversion) and final outcomes of MDR/XDR-TB patients with and without DM, managed at the national TB reference centre in Mexico City.</p></div><div><h3>Results</h3><p>Ninety patients were enrolled between 2010 and 2015: 73 with MDR-TB (81.1%), 11 with pre-XDR-TB (e.g. MDR-TB with additional resistance to one injectable drug or a fluoroquinolone, 12.2%) and 6 (6.7%) with XDR-TB. Out of these, 49 (54.4%) had DM and 42 (86%) were undergoing insulin treatment.</p><p>No statistically significant differences were found in treatment outcomes comparing DM vs. non-DM MDR-TB cases: 18/32 (56.3%) of DM cases and 19/24 (79.2%) non DM patients achieved treatment success (<em>p</em> <!-->=<!--> <!-->0.07). The time to sputum smear and culture conversion was longer (although not statistically) in patients without DM, as follows: the mean (±SD) time to sputum smear conversion was 53.9 (±31.4) days in DM patients and 65.2 (±34.8) days in non-DM ones (<em>p</em> <!-->=<!--> <!-->0.15), while the time to culture conversion was 66.2 (±27.6) days for DM and 81.4 (±37.7) days for non-DM MDR-TB cases (<em>p</em> <!-->=<!--> <!-->0.06).</p></div><div><h3>Conclusions</h3><p>The study results support the Mexican National TB programme to strengthen its collaboration with the DM programme, as an entry point for TB (and latent TB infection) screening and management.</p></div>","PeriodicalId":101122,"journal":{"name":"Revista Portuguesa de Pneumologia (English Edition)","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.rppnen.2016.11.009","citationCount":"18","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Portuguesa de Pneumologia (English Edition)","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2173511516301439","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 18

Abstract

Diabetes mellitus (DM) is a well-known risk factor for tuberculosis (TB). However, it is not known to what extent DM affects the outcome in patients with multidrug-resistant (MDR-TB) and extensively drug-resistant TB (XDR-TB) treated with second-line anti-TB drugs.

The objective of this study was to compare the microbiological evolution (sputum smear and culture conversion) and final outcomes of MDR/XDR-TB patients with and without DM, managed at the national TB reference centre in Mexico City.

Results

Ninety patients were enrolled between 2010 and 2015: 73 with MDR-TB (81.1%), 11 with pre-XDR-TB (e.g. MDR-TB with additional resistance to one injectable drug or a fluoroquinolone, 12.2%) and 6 (6.7%) with XDR-TB. Out of these, 49 (54.4%) had DM and 42 (86%) were undergoing insulin treatment.

No statistically significant differences were found in treatment outcomes comparing DM vs. non-DM MDR-TB cases: 18/32 (56.3%) of DM cases and 19/24 (79.2%) non DM patients achieved treatment success (p = 0.07). The time to sputum smear and culture conversion was longer (although not statistically) in patients without DM, as follows: the mean (±SD) time to sputum smear conversion was 53.9 (±31.4) days in DM patients and 65.2 (±34.8) days in non-DM ones (p = 0.15), while the time to culture conversion was 66.2 (±27.6) days for DM and 81.4 (±37.7) days for non-DM MDR-TB cases (p = 0.06).

Conclusions

The study results support the Mexican National TB programme to strengthen its collaboration with the DM programme, as an entry point for TB (and latent TB infection) screening and management.

墨西哥合并和不合并糖尿病的耐多药结核病患者细菌学转化和治疗结果的比较:初步数据
众所周知,糖尿病(DM)是结核病(TB)的危险因素。然而,目前尚不清楚糖尿病对接受二线抗结核药物治疗的耐多药结核病(MDR-TB)和广泛耐药结核病(XDR-TB)患者的预后有多大影响。本研究的目的是比较墨西哥城国家结核病参考中心管理的伴有和不伴有糖尿病的耐多药/广泛耐药结核病患者的微生物进化(痰涂片和培养转化)和最终结果。结果2010 - 2015年共纳入90例患者,其中耐多药结核73例(81.1%),前广泛耐药结核11例(如耐多药结核同时对一种注射药物或氟喹诺酮类药物产生额外耐药性,12.2%),广泛耐药结核6例(6.7%)。其中49例(54.4%)患有糖尿病,42例(86%)正在接受胰岛素治疗。糖尿病与非糖尿病型耐多药结核病患者的治疗结果无统计学差异:18/32(56.3%)的糖尿病患者和19/24(79.2%)的非糖尿病患者治疗成功(p = 0.07)。非糖尿病患者痰涂片和培养转化时间较长(无统计学意义),DM患者痰涂片转化平均(±SD)时间为53.9(±31.4)天,非DM患者为65.2(±34.8)天(p = 0.15), DM患者培养转化时间为66.2(±27.6)天,非DM耐多药结核病患者培养转化时间为81.4(±37.7)天(p = 0.06)。研究结果支持墨西哥国家结核病规划加强与糖尿病规划的合作,作为结核病(和潜伏性结核病感染)筛查和管理的切入点。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信